

June 21th, 2010

Change of company name for Biovitrum AB (publ)

Biovitrum AB (publ) will be listed under its new company name, Swedish Orphan Biovitrum AB (publ) with effect from June 24, 2010.

New short name:	SOBI
Unchanged ISIN code:	SE0000872095
Unchanged Round lot:	1
Unchanged orderbook ID:	36316

For more information please contact: Swedish Orphan Biovitrum AB (publ)

Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@sobi.com

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO:BVT) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 21, 2010 at 4 p.m. CET.